163 related articles for article (PubMed ID: 24751753)
21. Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies.
Madanchi N; Bitzan M; Takano T
Can J Kidney Health Dis; 2017; 4():2054358117698667. PubMed ID: 28540057
[TBL] [Abstract][Full Text] [Related]
22. Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease.
Papakrivopoulou E; Shendi AM; Salama AD; Khosravi M; Connolly JO; Trompeter R
Nephrology (Carlton); 2016 Oct; 21(10):893-900. PubMed ID: 26860320
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome.
Sinha A; Bhatia D; Gulati A; Rawat M; Dinda AK; Hari P; Bagga A
Nephrol Dial Transplant; 2015 Jan; 30(1):96-106. PubMed ID: 25121488
[TBL] [Abstract][Full Text] [Related]
24. Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial.
Kopp JB; Winkler CA; Zhao X; Radeva MK; Gassman JJ; D'Agati VD; Nast CC; Wei C; Reiser J; Guay-Woodford LM; Pollak MR; Hildebrandt F; Moxey-Mims M; Gipson DS; Trachtman H; Friedman AL; Kaskel FJ;
J Am Soc Nephrol; 2015 Jun; 26(6):1443-8. PubMed ID: 25573908
[TBL] [Abstract][Full Text] [Related]
25. Genetic homogeneity but IgG subclass-dependent clinical variability of alloimmune membranous nephropathy with anti-neutral endopeptidase antibodies.
Vivarelli M; Emma F; Pellé T; Gerken C; Pedicelli S; Diomedi-Camassei F; Klaus G; Waldegger S; Ronco P; Debiec H
Kidney Int; 2015 Mar; 87(3):602-9. PubMed ID: 25565308
[TBL] [Abstract][Full Text] [Related]
26. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.
Chen Y; Schieppati A; Chen X; Cai G; Zamora J; Giuliano GA; Braun N; Perna A
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD004293. PubMed ID: 25318831
[TBL] [Abstract][Full Text] [Related]
27. When should a nephrologist suspect a mitochondrial disease?
Cavero T; Rabasco C; Molero A; Blázquez A; Hernández E; Martín MA; Praga M
Nefrologia; 2015; 35(1):6-17. PubMed ID: 25611829
[TBL] [Abstract][Full Text] [Related]
28. COL4A3 mutations cause focal segmental glomerulosclerosis.
Xie J; Wu X; Ren H; Wang W; Wang Z; Pan X; Hao X; Tong J; Ma J; Ye Z; Meng G; Zhu Y; Kiryluk K; Kong X; Hu L; Chen N
J Mol Cell Biol; 2014 Dec; 6(6):498-505. PubMed ID: 25596306
[TBL] [Abstract][Full Text] [Related]
29. Positive role of rituximab in switching from cyclosporine to mycophenolate mofetil for children with high-dose steroid-dependent nephrotic syndrome.
Fujinaga S; Sakuraya K; Yamada A; Urushihara Y; Ohtomo Y; Shimizu T
Pediatr Nephrol; 2015 Apr; 30(4):687-91. PubMed ID: 25576066
[TBL] [Abstract][Full Text] [Related]
30. Focal and segmental glomerulosclerosis: clinical and kidney biopsy correlations.
Sethi S; Zand L; Nasr SH; Glassock RJ; Fervenza FC
Clin Kidney J; 2014 Dec; 7(6):531-7. PubMed ID: 25503953
[TBL] [Abstract][Full Text] [Related]
31. Treatment of severe lupus nephritis: the new horizon.
Chan TM
Nat Rev Nephrol; 2015 Jan; 11(1):46-61. PubMed ID: 25421826
[TBL] [Abstract][Full Text] [Related]
32. Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis.
Jones RB
Nephron Clin Pract; 2014; 128(3-4):243-9. PubMed ID: 25401382
[TBL] [Abstract][Full Text] [Related]
33. The treatment of idiopathic focal segmental glomerulosclerosis in adults.
Hogan J; Radhakrishnan J
Adv Chronic Kidney Dis; 2014 Sep; 21(5):434-41. PubMed ID: 25168833
[TBL] [Abstract][Full Text] [Related]
34. Membranoproliferative glomerulonephritis with IgA deposits in patients with alcoholic cirrhosis.
Ferrario G; Palazzi P; Torri Tarelli L; Volpi A; Meroni M; Giordano F; Sessa A
Pathologica; 1986; 78(1056):469-78. PubMed ID: 3615024
[No Abstract] [Full Text] [Related]
35. Amelioration of the adverse effects of prednisolone by rituximab treatment in adults with steroid-dependent minimal-change nephrotic syndrome.
Miyabe Y; Takei T; Iwabuchi Y; Moriyama T; Nitta K
Clin Exp Nephrol; 2016 Feb; 20(1):103-10. PubMed ID: 26138356
[TBL] [Abstract][Full Text] [Related]
36. Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome.
Fenoglio R; Sciascia S; Beltrame G; Mesiano P; Ferro M; Quattrocchio G; Menegatti E; Roccatello D
Oncotarget; 2018 Jun; 9(48):28799-28804. PubMed ID: 29989000
[TBL] [Abstract][Full Text] [Related]
37. Rituximab and Therapeutic Plasma Exchange in Recurrent Focal Segmental Glomerulosclerosis Postkidney Transplantation.
Alasfar S; Matar D; Montgomery RA; Desai N; Lonze B; Vujjini V; Estrella MM; Manllo Dieck J; Khneizer G; Sever S; Reiser J; Alachkar N
Transplantation; 2018 Mar; 102(3):e115-e120. PubMed ID: 29189487
[TBL] [Abstract][Full Text] [Related]
38. Single dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome.
Niu XL; Hao S; Wang P; Zhang W; Guo GM; Wu Y; Kuang XY; Zhu GH; Huang WY
Biomed Rep; 2016 Aug; 5(2):237-242. PubMed ID: 27446549
[TBL] [Abstract][Full Text] [Related]
39. Nephrotic syndrome: Efficacy of rituximab in challenging nephrotic syndrome.
Lemley KV; Mak RH
Nat Rev Nephrol; 2015 May; 11(5):257-8. PubMed ID: 25752834
[TBL] [Abstract][Full Text] [Related]
40. Monoclonal antibodies for renal diseases: current concepts and ongoing treatments.
Santoro D; Pellicanò V; Visconti L; Trifirò G; Cernaro V; Buemi M
Expert Opin Biol Ther; 2015; 15(8):1119-43. PubMed ID: 26087994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
